Search results
Results from the WOW.Com Content Network
The F.A. Davis Company counts both faculty and students among its readers today. Its flagship publications, Taber’s Cyclopedic Medical Dictionary and Davis's Drug Guide for Nurses, as well as its online and mobile references, are trusted resources for healthcare professionals around the globe.
Squibb filed for U.S. patent protection on the drug in February 1976, which was granted in September 1977, and captopril was approved for medical use in 1980. [4] It was the first ACE inhibitor developed and was considered a breakthrough both because of its mechanism of action and also because of the development process.
Parke-Davis is a subsidiary of the pharmaceutical company Pfizer. Although Parke, Davis & Co. is no longer an independent corporation, it was once America's oldest and largest drug maker, and played an important role in medical history. In 1970 Parke-Davis was acquired by Warner–Lambert, which in turn was acquired by Pfizer in 2000. [2]
Methohexital or methohexitone (marketed under the brand names Brevital and Brietal) is a drug which is a barbiturate derivative. It is classified as short-acting, and has a rapid onset of action. [2] It is similar in its effects to sodium thiopental, a drug with which it competed in the market for anesthetics.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments:
Daniel M. Davis has a doctorate in physics from Strathclyde University. He was professor of molecular immunology at Imperial College London and director of research at the University of Manchester's collaborative centre for inflammation research. [1] [2] Davis is a recognised as an expert in the field by the Nature journal of immunology.
Tesla CEO Elon Musk’s embrace of President-elect Donald Trump is paying off for Tesla shareholders, with the stock jumping nearly 15% on Wednesday.But the question investors are asking is what ...